诺和诺德全面裁撤糖尿病细胞疗法部门 涉及约250名员工

格隆汇
Oct 11

丹麦制药商诺和诺德宣布裁撤其细胞疗法部门,该部门负责第一型糖尿病的药物研发。该公司在声明中表示,正寻求合作伙伴以继续推进相关研究。据悉,该部门约250名员工几乎全数被裁,诺和诺德未透露更多具体细节。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10